sodium–glucose cotransporter 2 inhibitors Archives

Home sodium–glucose cotransporter 2 inhibitors

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Article Type

Review

Published

04 Jan 2023

This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Edgardo Kaplinsky MD

Article Type

Review

Published

28 Feb 2020

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.